AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Jan 4, 2021
31542_dirs_2021-01-04_95816bb3-898e-4676-9e02-9307756d7926.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2020-12-30
Reporting Person: INGENITO GARY (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-30 | Options to purchase common stock | $3.42 | A | 200000 | Acquired | 2027-12-30 | Common Stock (200000) | Direct |
Footnotes
F1: Options vest in equal tranches, 1/3rd on December 30, 2021, 1/3rd on December 30, 2022 and 1/3rd on December 30, 2023.disagreements with the Company on any matter relating to the Company's operations, policies and practices. Dr. Ingenito remains an officer of the Company.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6